Clinical studies show that most myocardial damage occurs within the first two hours after coronary occlusion.

The ALERTS trial design provides a clinical environment to test the efficacy of a device that may significantly reduce time to treatment and thus may decrease heart muscle damage and improve survival rates related to major cardiac events.

After a successful Phase One study in the US, the AngelMed Guardian System is presently being tested in the ALERTS pivotal study.   The system is currently available for investigational use only in the US.

AngelMed is currently signing on clinical research sites and enrolling patients in the ALERTS study.